Endometrial Cancer-Infiltrating Mesenchymal Stem Cells Exhibit Immunosuppressive Effects

Kai-Hung Wang¹, Yu-Hsun Chang², Tomor Harnod³, and Dah-Ching Ding⁴,⁵

Abstract
Endometrial cancer is the most common gynecologic cancer with high heterogeneity. However, there are limited treatment options for advanced endometrial carcinoma. In recent years, immunotherapy has broadly been used for the treatment of various cancers. However, the efficacy of immunotherapy against endometrial cancer is limited. The tumor microenvironment, including mesenchymal stem cells (MSCs), may contribute to tumor progression through cancer cells themselves and through cells of the immune system. We successfully isolated endometrial cancer–derived MSCs (EmCaMSCs) from patients and found that the population of MSCs in tumor tissues was approximately 1%–5%. The population of MSCs correlated with the stage of the disease. EmCaMSCs expressed MSC markers and exhibited trilineage differentiation ability. The programmed death ligands PD-L1 and PD-L2 were highly expressed in EmCaMSCs; their expression could be further enhanced by tumor necrosis factor-α and interferon-γ. When cocultured with peripheral blood mononuclear cells (PBMCs), anti-CD3, and anti-CD28, EmCaMSCs inhibited the proliferation of PBMCs, which were partially rescued by treatment with anti-PD-L1 antibodies. From the profile of conditioned medium of EmCaMSCs, we discovered that interleukin (IL)-8 and insulin-like growth factor–binding protein 6 could also rescue the proliferation of PBMCs. Furthermore, EmCaMSCs cocultured with IL-2-induced PBMCs exhibited decreased expression of CD56, CD4, and CD8 and showed decreased cytotoxicity toward K562 cells and endometrial cancer cells. Overall, EmCaMSCs were isolated successfully from endometrial cancer tissues and exhibited immunosuppressive effects and may be targeted for the treatment of endometrial cancer by anti-cytokine and immune checkpoint inhibitors. The percentage of MSCs in tumor stroma might predict the prognosis of endometrial cancer.

Keywords
mesenchymal stem cells, immunosuppression, tumor microenvironment, endometrial cancer

Introduction
Uterine cancer is the most common gynecologic cancer in the United States and Taiwan¹,², and endometrial cancers comprise more than 90% of all uterine cancers³. Unopposed estrogen secretion contributes to the risk of endometrial cancer. Current treatments are staging surgery and adjuvant radiotherapy or chemotherapy for advanced stage³. However, women with recurrent or metastatic endometrial cancer have limited treatment options and show poor prognoses. Therefore, there is an urgent need for new therapies for the treatment of this disease⁴.

Endometrial cancer can be divided into four molecular subtypes including the polymerase ε (POLE) ultra-mutated and microsatellite instability (MSI) hypermutated types⁵. POLE ultra-mutated and MSI-high endometrial cancers are abundantly infiltrated with T cells and show high expressions of high programmed death-1 (PD-1) and programmed...
CaMSC-secreted interleukin (IL)-8 is involved in promoting tumor progression. CaMSCs may promote tumor progression via specific cytokines. We hypothesized that endometrial CaMSCs may exhibit cytokines and PD-L1-mediated immunosuppressive effects in the tumor microenvironment. This study aimed to analyze whether endometrial CaMSCs harbor PD-L1-mediated immunosuppression or cytokines to promote cancer in the tumor microenvironment.

**Materials and Methods**

**Ethics**

This study was approved by the Research Ethics Committee of Hualien Tzu Chi Hospital (IRB 109-257-A), and informed consent was obtained from all the patients included in the study. We confirm that all experiments were performed in accordance with the relevant named guidelines and regulations.

Endometrial cancer patients were included if they were >18 years of age, female, and had been admitted for staging surgery after biopsy-proven endometrial cancer.

**Clinical Specimens and Isolation of Endometrial CaMSCs**

The specimens of endometrial cancer tissue were cut into small pieces, digested with type I collagenase (Worthington Biochemical Corporation, Lakewood, NJ, USA), and incubated for 1–2 h at 37°C in a humidified atmosphere under 5% CO₂. The samples were passed through 70 μm and 40 μm cell strainers (Falcon) to collect single cells. After washing out the collagenase with phosphate-buffered saline (PBS), the cells were seeded into six-well plates containing low-glucose Dulbecco’s Modified Eagle medium (DMEM; Gibco, Waltham, MA, USA), supplemented with 10% fetal bovine serum (FBS; Gibco) and 1× penicillin/streptomycin (Gibco). The medium was refreshed, and cells were expanded every 2–3 days. Briefly, endometrial cancer–derived MSCs (EmCaMSCs) before P8 (8-passages) were used in the experiments.

**Isolation of Bone Marrow MSCs and Wharton’s Jelly MSCs**

Bone marrow MSCs (BMSCs) were collected under ethical approval (IRB number: IRB103-49-A). Bone marrow was aspirated from patients with bone trauma who underwent orthopedic surgery. First, 5 ml of bone marrow aspirate was mixed with 5 ml of PBS. Then, the mixed bone marrow aspirate was centrifuged at 1,200 × g for 6 min, and the supernatant was removed. The resultant pellet was plated on a culture dish with a culture medium (alpha-MEM, 15% FBS, and 1% penicillin/streptomycin).

All the experiments that required collection of Wharton’s jelly MSCs (WJ-MSCs) were approved by the Research Ethics Committee of Buddhist Tzu Chi General Hospital (IRB 100-166), and written consent was obtained from all study participants. The detailed derivation protocol for WJ-MSCs has been previously reported. Briefly, one human umbilical cord sample (20 cm in length, 20 g in weight) was collected, and separation of Wharton’s jelly from the vessels and the amniotic membrane was conducted within 24 h. The jelly was then cut into pieces smaller than 0.5 cm³, treated with collagenase type 1 (Sigma, St Louis, MO, USA), and incubated for 14–18 h at 37°C in a 95% air/5% CO₂ humidified atmosphere. The explants were then cultured in low-glucose DMEM containing 10% FBS and antibiotics at 37°C in a 95% air/5% CO₂ humidified atmosphere. They were left undisturbed for 5–7 days to allow for the migration of cells from the explants. The resultant MSCs were WJ-MSCs.

**Flow Cytometry**

The cells were stained with fluorescent dye–conjugated antibodies for 30 min on ice and washed twice with PBS. After resuspending in PBS containing 2% FBS, the cells were analyzed by fluorescence-activated cell sorting (FACS Calibur; BD Biosciences, Franklin, NJ, USA). The following antibodies were used in the analysis: CD34-FITC, CD73-FITC, CD90-FITC, CD90-PE, human leukocyte antigen (HLA)-ABC-FITC, HLA-DR-FITC (eBioscience, San Diego, CA, USA); CD44-FITC, CD105-APC (BD Biosciences); CD45-ABC-FITC, HLA-DR-FITC (eBioscience, San Diego, CA, USA). In the case of fresh tissues, CD73-FITC, CD90-PE, and CD105-APC were used for triple staining. Antibodies against PD-L1-PE and PD-L2-APC were purchased from eBioscience.

**Differentiation Into Adipocytes, Osteoblasts, and Chondrocytes**

For adipogenesis, EmCaMSCs were cultured in DMEM containing 10% FBS, 1 mmol/l dexamethasone, 5 mg/ml insulin, 0.5 mmol/l isobutylmethylxanthine, and 60 mmol/l indomethacin (all from Sigma-Aldrich, St. Louis, MO, USA) for 2 weeks. Cells were stained with Oil Red O (Sigma-Aldrich); the intracellular lipid droplets showed positive signals. To investigate osteogenesis, EmCaMSCs were cultured in DMEM supplemented with 10% FBS, 0.1 mmol/l dexamethasone, 10 mmol/l β-glycerol phosphate, and 50 mmol/l ascorbate for 2 weeks. Positive staining with alizarin red S...
(Sigma-Aldrich) was indicative of mineralized calcium deposits, which are characteristic of osteoblasts. For chondrogenesis, EmCaMSCs were loaded into the bottom of 15 ml conical tubes containing DMEM medium supplemented with 10% FBS, 10 ng/mL transforming growth factor β1 (PeproTech, Rocky Hill, NJ, USA), 50 μg/ml ascorbic acid 2-phosphate (Sigma-Aldrich), and 6.25 μg/ml insulin (Sigma-Aldrich) and incubated for 3 weeks. The formed cartilage was fixed in 4% paraformaldehyde for 24 h before transferring to 70% ethanol for an additional 24 h. It was then embedded in an optimal cutting temperature compound, cryosectioned, and stained with Safranin O, Aggrecan, and type II collagen.

**Immunohistochemical Analysis**

Briefly, the cryosectioned samples of chondrocytes (5–8 μm) were stained with Safranin O, anti-Aggrecan, and anti–type II collagen (1:200; Sigma-Aldrich) at 4°C overnight. After washing with PBS/Tween, the sections were incubated with secondary antibodies at room temperature for 1 h, and further stained with 3,3′-diaminobenzidine chromogen and hematoxylin (Sigma-Aldrich). Brown coloration was an indicator of protein expression.

**Quantitative RT-PCR**

Total RNA was purified using a PureLink RNA Mini kit (Life Technologies, Carlsbad, CA, USA), according to the manufacturer’s instructions. Briefly, 1 μg of total RNA was reverse transcribed into cDNA using SuperScript III enzyme (Invitrogen, Carlsbad, CA, USA), as per the manufacturer’s instruction. A real-time polymerase chain reaction (RT-PCR) was performed using the Fast SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) and analyzed using Quant Studio 5 (Applied Biosystems). The glyceraldehyde-3-phosphate dehydrogenase gene was used as an internal control, and all of the experiments were conducted in triplicate. The primer sequences used are listed in Supplementary Table 1.

**Enzyme-Linked Immunosorbent Assay (ELISA)**

Concentrations of IL-8, IGFBP2, and IGFBP6 were determined using an ELISA Kit (Abcam) according to the instructions of the manufacturer. Briefly, the diluted CM of EmCaMSCs was incubated with antibody-coating plates for 1 h. After washing, the plates were incubated with a streptavidin-horseradish peroxidase solution for 30 min and chromogen for 10 min. The reaction was stopped and the absorbance measured at 450 nm for the primary signal and 620 nm for a reference signal. The results were calculated by OD450 minus OD620 and blank and fitted into the standard curve to determine the concentration of target proteins.

**Cytotoxicity Assay of PBMCs Cocultured With EmCaMSCs**

Briefly, PBMCs were cocultured with EmCaMSC2 and EmCaMSC3 in the presence of IL-2 (3,000 U/ml; Gibco) for 4 days. The ratio of PBMCs to EmCaMSCs was 10:1. PBMCs were harvested and then further cocultured with K562 cells in ratios of 5:1 and 10:1 for 4 h. The medium was
replaced with PBS containing 2% FBS and fresh IL-2. Cells were harvested and stained with propidium iodide (PI) (Sigma-Aldrich) for 10 min. The K562 cells could be separated by forward scatter/side scatter, and the proportion of PI-positive K562 cells was calculated. For the cytotoxicity test in endometrial cancer cells, RL95-2 and HEC-1A were seeded and cultured overnight. After attaching cells, PBMCs were cocultured with EmCaMSCs as above or with anti-CD3/CD28 for 4 days and were further cocultured with cancer cells at a 10:1 ratio for 6 h with IL-2 or anti-IL-8, anti-IGFBP2, and anti-IGFBP6. The supernatants were collected for lactate dehydrogenase (LDH) activity test (Thermo-Fisher, Waltham, MA, USA) following the manufacturer’s instructions. PBMCs cultured alone and treated with IL-2 or anti-CD3/CD28 served as the control. All of the experiments were conducted in triplicate.

Statistical Analyses
We compared the two groups using an independent-samples t-test or Wilcoxon rank-sum test for continuous variables and the chi-square test for categorical variables. For more than two groups, we used analysis of variance (ANOVA) with a post hoc test (Bonferroni test). SPSS software (version 24; IBM, NY, USA) was used for statistical analysis. A P value <0.05 was considered statistically significant.

Results
Composition, Isolation, and Characterization of EmCaMSCs
Typical MSCs tend to express major MSC surface markers, including CD73, CD90, and CD105, and exhibit the ability to differentiate into adipocytes, chondrocytes, and osteoblasts\(^\text{13}\). Therefore, we used triple staining to determine the size of the MSC population (Fig. 1A). The proportion of EmCaMSCs was associated with the stage of the disease (\(P < 0.05\), Fig. 1B).

Subsequently, the CaMSCs were successfully isolated from endometrial cancer patients and their nature was confirmed by analyzing other markers. Like MSCs obtained from other sources, EmCaMSCs expressed CD44, CD73, CD90, CD105, and HLA-ABC, but lacked CD34, CD45, and HLA-DR (Fig. 2A). Furthermore, these EmCaMSCs showed the ability to successfully differentiate into adipocytes (positive oil red staining), osteoblasts (positive alizarin red S staining) (Fig. 2B), and chondrocytes (positive Safranin O staining) (Fig. 2C). Immunohistochemistry also showed
Figure 2. Characterization and trilineage differentiation of endometrial cancer–derived mesenchymal stem cells (EmCaMSCs).
(A) Representative flow cytometry histograms of EmCaMSCs at passage 3. The EmCaMSCs were positive for CD29, CD44, CD90, CD105, and HLA-ABC, but negative for CD34, CD45, and HLA-DR. (B) After culturing in adipogenic media for 14 days, positive staining with Oil Red O was observed (upper panel). After culturing in osteogenic media for 14 days, osteogenesis was confirmed by positive staining with alizarin red (lower panel). The right panel shows the quantification of Oil Red and alizarin red OD ratio in differentiated adipocytes and osteoblasts. **P < 0.01, ***P < 0.001. (C) After 21 days of chondrogenesis, the formatted three-dimensional pallet showed positive Safranin O, aggrecan, and type 2 collagen staining. Scale bar = 100 µm. All of the EmCaMSCs for the experiments were conducted in triplicate.
positive staining for aggrecan and type II collagen (chondrocyte markers) (Fig. 2C).

Clinical Information of the Patients and Cell Characteristics of EmCaMSCs

The clinical information of the patients who provided EmCaMSCs is listed in Table 1. In the following experiments, we used EmCaMSC2 and EmCaMSC3 because there were no MSCs in the tumor for EmCaMSC1. One early-stage and one advanced-stage EmCaMSC were used for further experiments. The three patients were without classical risk factors such as hypertension, diabetes mellitus, and high body mass index (BMI). Two patients had childbirth histories. All three EmCaMSCs met classical MSC characteristics (CD marker panels and differentiation capabilities)\textsuperscript{14}.

PD-L1 and PD-L2 Are Expressed in EmCaMSCs

Subsequently, we used quantitative RT-PCR (qRT-PCR) and flow cytometry to check whether EmCaMSCs expressed PD-L1 and PD-L2. qRT-PCR revealed that the PD-L1 and PD-L2 genes were expressed in EmCaMSCs (\(n = 3\), Fig. 3A). Moreover, flow cytometry showed that protein expression could also be increased (~1.6-fold in PD-L1 and ~2.4-fold in PD-L2) by treatment with TNF\(\alpha\) and IFN\(\gamma\) (Fig. 3B and C). Overall, gene and protein expressions of PD-L1 and PD-L2 were observed in EmCaMSCs.

EmCaMSCs Suppressed PBMC Proliferation and Could be Partially Reversed by Inhibiting PD-L1

Next, we evaluated the ability of EmCaMSCs to inhibit PBMC proliferation. We directly cocultured EmCaMSCs and PBMCs and treated them with anti-CD3 and anti-CD28 antibodies for 3 days to enhance T-cell proliferation. Figure 4A shows the morphology of EmCaMSCs (a), PBMCs (b), cocultured EmCaMSCs and PBMCs (c), and cocultured EmCaMSCs and PBMCs plus IFN\(\gamma\) (d). We noted that PBMCs formed large colonies when they were not cocultured; coculturing with EmCaMSCs reduced the size of the colonies. We found that the inhibition of PBMC proliferation was dependent on the ratio between EmCaMSCs and PBMC (1:1, 1:2, 1:4, and 1:8; \(P < 0.001\); Fig. 4B). Treatment of EmCaMSCs with IFN\(\gamma\) significantly enhanced this inhibitory effect (Fig. 4C). After being treated with nivolumab and/or anti-PD-L1 antibodies, the proliferation of PBMCs (cocultured with EmCaMSCs) was increased 2- to 2.5-fold (\(P < 0.05\)) (Fig. 4D). These results demonstrated that EmCaMSCs could suppress the proliferation of PBMCs through cell–cell contact and could be blocked by inhibiting PD-L1.

EmCaMSC-Secreted IL-8 and IGFBP6 Could Suppress PBMC Proliferation

To further investigate the other mechanisms, we tested the composition of EmCaMSC-CM and found that IGFBP2, IGFBP4, IGFBP6, IL-8, OPG, TIMP-1, and TIMP-2 were
Figure 3. Baseline and induced expression of programmed death ligands, PD-L1 and PD-L2, in endometrial cancer–derived mesenchymal stem cells (EmCaMSCs). The expression of PD-L1 and PD-L2 was analyzed by (A) quantitative reverse transcription-polymerase chain reaction and (B) fluorescence-activated cell sorting. After treating with tumor necrosis factor-α (10 ng/ml) and interferon-γ (100 ng/ml) for 24 h, the protein expression of PD-L1 and PD-L2 was (B) analyzed by fluorescence-activated cell sorting and (C) quantified on the basis of mean fluorescence intensity. All of the experiments were conducted in triplicate. *** \( P < 0.001 \).

Figure 4. The function of programmed death ligands, PD-L1 and PD-L2, in the proliferation of peripheral blood cells (PBMCs) cocultured with endometrial cancer–derived mesenchymal stem cells (EmCaMSCs). (A) The morphology of PBMCs cocultured with EmCaMSCs, anti-CD3 antibodies (5 µg/ml), and anti-CD28 antibodies (5 µg/ml) for 3 days. From left: EmCaMSCs only, PBMC only, PBMC cocultured with EmCaMSCs, PBMC cocultured with EmCaMSCs and interferon-γ. (B) The proliferation of PBMCs cocultured with EmCaMSCs in different ratios (EmCaMSCs:PBMC). PBMCs cultured alone (0:1, 0:2, 0:4, 0:8) were used as a control. (C) The proliferation of PBMCs cocultured with EmCaMSCs and interferon-γ. (D) The fold change in the proliferation of PBMCs cocultured with EmCaMSCs plus nivolumab and/or anti-PD-L1 antibodies. EmCaMSC2 and EmCaMSC3 were used in the experiments, which were conducted in triplicate. * \( P < 0.05 \), ** \( P < 0.01 \), *** \( P < 0.001 \).
highly expressed from ~2- to 3-fold (Fig. 5A and B). The ELISA results confirmed IL-8 (Fig. 5C), IGFBP2 (Fig. 5D), and IGFBP6 (Fig. 5E) concentrations in the CM of various EmCaMSCs (Table 2). EmCaMSCs could secrete a considerable amount of the above three cytokines when compared with the control medium. Furthermore, we wanted to determine the effects of these cytokines on PBMC proliferation when cocultured with EmCaMSCs. We found that IL-8 could decrease the proliferation of PBMCs, and inhibition of IL-8 would increase the proliferation of PBMCs when cocultured with EmCaMSCs (Fig. 5F). Besides, inhibition of IGFBP6, but not IGFBP2, could also increase the proliferation of PBMCs when cocultured with EmCaMSCs (Fig. 5G). Moreover, we tested the effects of these cytokines and anti-PD-L1 separately or in combination on the proliferation of CD4 and CD8 cells when cocultured with EmCaMSCs. The results showed that the combination of three cytokine antibodies could significantly recover CD4 and CD8 cell proliferation.
of the characteristics and functions of EmCaMSCs may contribute to tumor progression and evolution. Tumor MSCs can secrete cytokines and chemokines, which can affect tumor growth and metastasis. Therefore, crosstalk between various cells (MSCs, tumor cells, surrounding host tissue) in the tumor microenvironment will contribute to tumor progression and evolution. Tumor MSCs can be a therapeutic target. In our study, CaMSCs were found to have an immunosuppression effect in the tumor microenvironment. If immunomodulation medications are used, then tumors can be killed by the patient's own immune cells. Despite the therapeutic value of tumor MSCs, the percentage of tumor MSCs might predict the prognosis of the patients.

Table 2. Concentrations of Various Cytokines of EmCaMSCs.

| Cytokines (mean ± SD) | Control  | EmCaMSC1 | EmCaMSC2 | EmCaMSC3 |
|-----------------------|----------|----------|----------|----------|
| IL-8 (pg/ml)          | 240.2 ± 2.9 | 324.9 ± 7.2 | 314.5 ± 37.5 | 990.2 ± 31.6 |
| IGFBP2 (ng/ml)        | 75.2 ± 3.0  | 364.6 ± 3.6 | 1,228.6 ± 31.8 | 513.8 ± 5.8  |
| IGFBP6 (ng/ml)        | 0.0 ± 0.0   | 9.3 ± 1.0  | 19.8 ± 1.1  | 7.6 ± 0.6   |

EmCaMSC: endometrial cancer–derived mesenchymal stem cell; SD: standard deviation.

Discussion

In this study, for the first time, we successfully isolated CaMSCs from an endometrial tumor. Like BMSCs, these EmCaMSCs also displayed the ability to differentiate into adipocytes, osteoblasts, and chondrocytes. EmCaMSCs were able to inhibit the proliferation of PBMCs and CIK cell cytotoxicity; this indicated that EmCaMSCs may have immunosuppressive effects, which contribute to tumor progression and the failure of immunotherapy. Therefore, an understanding of the characteristics and functions of EmCaMSCs may promote the development of novel therapeutic strategies for the treatment of endometrial cancers.

The cancer microenvironment contains numerous cell types, including endothelial cells, lymphatic circulation, fibroblasts, and various cells derived from bone marrow, such as MSCs and macrophages. Tumor cells can secrete chemokines and growth factors to attract MSCs to the tumor sites. Tumor MSCs can secrete cytokines and chemokines, which can affect tumor growth and metastasis. Therefore, crosstalk between various cells (MSCs, tumor cells, surrounding host tissue) in the tumor microenvironment will contribute to tumor progression and evolution. Tumor MSCs can be a therapeutic target. In our study, CaMSCs were found to have an immunosuppression effect in the tumor microenvironment. If immunomodulation medications are used, then tumors can be killed by the patient's own immune cells. Despite the therapeutic value of tumor MSCs, the percentage of tumor MSCs might predict the prognosis of the patients.

Previous studies reported that tumor MSCs secreted CCL5, which can stimulate breast cancer cell migration, invasion, and metastasis and stimulate PD-L1 expression to suppress immune response. When tumor cells are mixed with MSCs (adult or fetal origin), tumor growth is promoted in vivo more than without mixing with MSCs. BMSCs can promote cell proliferation of multiple myeloma through PD-1/PD-L1 inhibition of immune response. Sun et al. showed that gastric cancer MSC-derived IL-8 could induce PD-L1 expression in gastric cancer cells via the STAT3/mTOR-c-myel signaling pathway. These authors found that block IL-8 derived from MSCs may overcome immune escape induced by PD-L1. Enhanced PD-L1 expression of cancer stromal cells can inhibit CD8+ T-cell immune response and promote colon cancer. In agreement with previous studies, our study also showed that CaMSCs could inhibit immune response via cytokines (IL-8, IGFBP2, and IGFBP6) and PD-L1, which attenuate the killing abilities of PBMC and T cells. EmCaMSCs expressed PD-L1 and PD-L2, similar to CaMSC derived from prostate cancer, but the expression of these ligands was further upregulated by treatment with TNFα and IFNγ. The PD-L1 promoter has an interferon regulatory factor 1 response element comprising an IFN-γ binding site. BMSCs could inhibit lymphocyte proliferation through the PD-1 pathway. Similar to BMSCs, adipose...
tissue–derived MSCs can also inhibit T cells via nuclear factor-κB (NFκB) activation, mediated by the PD-L1/PD-1 and galectin-9/TIM-3 pathways. In the present study, we showed that IFNγ could enhance the EmCaMSC-mediated inhibition of PBMC proliferation. However, we found that the inhibition of PD-L1 and PD-1 by anti-PD-L1 antibodies and nivolumab only partially reversed PBMC proliferation, suggesting that other factors may also be involved.

To identify additional possible molecules that may be involved in regulating PBMC proliferation, we analyzed the secreted proteins from EmCaMSC-CM and found that the expression of IGFBP2, IGFBP4, IGFBP6, IL-8, OPG, TIMP-1, and TIMP-2 was significantly higher. Other than PD-L1 and PD-1, we determined that PBMC proliferation could be rescued by inhibiting IL-8 and IGFBP6 under the EmCaMSC-PBMC coculture system. Gastric cancer MSCs enhanced PD-L1 expression of gastric cancer cells by secreting IL-8. Although it was reported that IGFBP2 increased PD-L1 expression in melanoma cells and promoted immunosuppression in glioblastoma, we did not find that IGFBP2 could rescue the proliferation of PBMC. We determined that IGFBP6 contributed to the immunosuppressive effects of EmCaMSCs potentially through the IGF-independent pathway. Thus, inhibition of IL-8 and IGFBP6 may attenuate the immunosuppressive effects of EmCaMSCs, and they could be additional targets for the immunotherapeutic regimen with anti-PD-1/PD-L1.

Furthermore, EmCaMSCs suppressed the cytotoxicity of IL-2–induced killer cells, possibly by directly inhibiting the CD56 and CD8 populations, which possess cytotoxic potential. In addition, tumor stromal cells impaired the cytotoxicity of natural killer (NK) cells by reducing the expression of the NK cell activation receptors NKp44 and NKp46. Further studies are needed to elucidate the mechanisms through which EmCaMSCs suppress IL-2–induced killer cell cytotoxicity.

Most studies about CaMSCs have focused on tumor cells and the production of some common cytokines, such as IL-6, showing the altered signaling pathways in different cancers and suggesting that they may have tissue-specific characteristics. Lung squamous cell carcinoma–derived MSCs were shown to block NK cell activity through IL-6 and prostaglandin E2 (PGE2). A previous study showed that prostate cancer–derived CaMSCs could inhibit T-cell proliferation through the PD-L1/PD-1 pathway. Collectively, it is suggested that CaMSCs regulate immunosuppression through various cytokines and other molecules, altering the efficacy of immunotherapy. However, due to the low proportion (1%–5%) of CaMSCs and their high similarity with normal MSCs, it is important for potential therapies to selectively target CaMSCs or CaMSC-dependent signaling pathways. Previous animal studies involved coinjecting animals with MSCs and cancer cells (1:1 ratio); however, this may not represent real-life scenarios, so the results should be re-evaluated.
In conclusion, we successfully isolated EmCaMSCs from patients with endometrial cancer and showed that they exhibited immunosuppressive effects. EmCaMSCs were found to suppress the proliferation of PBMCs via PD-L1, IL-8, IGFBP6, and IL-2-induced killer cytotoxicity. Anti-MSC-secreted cytokine therapy, an immune checkpoint inhibitor, or a combination may have therapeutic value against endometrial cancer. Furthermore, the percentage of EmCaMSCs may predict the prognosis of endometrial cancer.

Author Contributions
KH Wang: conception, study design, data collection, manuscript writing (draft); YH Chang: conception and data analysis; T Harnod: conception and manuscript writing (draft); DC Ding: supervision, manuscript writing (draft), manuscript revision.

Ethical Approval
This study was approved by the Research Ethics Committee of the Hualien Tzu Chi Hospital (IRB 109-257-A).

Statement of Human and Animal Rights
This article does not contain any studies with human or animal subjects.

Statement of Informed Consent
There are no human subjects in this article and informed consent is not applicable.

Data Availability
All relevant data are reported in the article.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work was supported by the Buddhist Tzu Chi Medical Foundation (TCMF-EP-108-02 and TCRD110-62).

ORCID iD
Dah-Ching Ding https://orcid.org/0000-0001-5105-068X

Supplemental material
Supplemental material for this article is available online.

References
1. Felix AS, Brinton LA. Cancer progress and priorities: uterine cancer. Cancer Epidemiol Biomarkers Prev. 2018;27(9): 985–94.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1): 7–33.
3. Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K, Veneris JL. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4): 258–79.
4. Barroso-Sousa R, Ott PA. PD-1 inhibitors in endometrial cancer. Oncotarget. 2017;8(63): 106169–70.
5. Yen TT, Wang TL, Fader AN, Shih IM, Gaillard S. Molecular classification and emerging targeted therapy in endometrial cancer. Int J Gynecol Pathol. 2020;39(1): 26–35.
6. Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriguez L, Kaufman HL, Ali S, et al. Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 2016;126(6): 2334–40.
7. Ott PA, Bang Y-J, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22): 2535–41.
8. Atilay F, Frisbie L, Pressimone C, Coffman L. Mesenchymal stem cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1234: 31–42.
9. Xu H, Zhou Y, Li W, Zhang B, Zhang H, Zhao S, Zheng P, Wu H, Yang J. Tumor-derived mesenchymal-stem-cell-secreted IL-6 enhances resistance to cisplatin via the STAT3 pathway in breast cancer. Oncol Lett. 2018;15(6): 9142–50.
10. Zhang X, Hu F, Li G, Li G, Yang X, Liu L, Zhang R, Zhang B, Feng Y. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis. 2018;9(2): 25.
11. Sun L, Wang Q, Chen B, Zhao Y, Shen B, Wang H, Xu J, Zhu M, Zhao X, Xu C, Chen Z, et al. Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis. Cell Death Dis. 2018;9(9): 928.
12. Ding DC, Shyu WC, Chiang MF, Lin SZ, Chang YC, Wang HJ, Su CY, Li H. Enhancement of neuroplasticity through upregulation of beta1-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobiol Dis. 2007;27(3): 339–53.
13. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4): 315–17.
14. Ding D-C, Shyu W-C, Lin S-Z. Mesenchymal stem cells. Cell Transplant. 2011;20(1): 5–14.
15. Lin W, Huang L, Li Y, Fang B, Li G, Chen L, Xu L. Mesenchymal stem cells and cancer: clinical challenges and opportunities. Biomed Res Int. 2019;2019:2820853.
16. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162): 557–63.
17. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J, Cao W, Han C, Chen Y. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol. 2006;80(3): 267–74.
18. Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol. 2008;130(6): 1091–103.

19. Aboulkheyr Es H, Bigdeli B, Zhand S, Aref AR, Thiery JP, Warkiani ME. Mesenchymal stem cells induce PD-L1 expression through the secretion of CCL5 in breast cancer cells. J Cell Physiol. 2021;236(5): 3918–28.

20. Chen D, Tang P, Liu L, Wang F, Xing H, Sun L, Jiang Z. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway. Cell Cycle. 2018;17(7): 858–67.

21. O’Malley G, Treacy O, Lynch K, Naicker SD, Leonard NA, Lohan P, Dunne PD, Ritter T, Egan LJ, Ryan AE. Stromal Cell PD-L1 inhibits CD8+ T-cell antitumor immune responses and promotes colon cancer. Cancer Immunol Res. 2018;6(11): 1426–41.

22. Krueger TE, Thorek DLJ, Meeker AK, Isaacs JT, Brennen WN. Tumor-infiltrating mesenchymal stem cells: drivers of the immunosuppressive tumor microenvironment in prostate cancer. Prostate. 2019;79(3): 320–30.

23. Lee S-J, Jang B-C, Lee S-W, Yang Y-I, Suh S-I, Park Y-M, Oh S, Shin J-G, Yao S, Chen L, Choi I-H, et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett. 2006;580(3): 755–62.

24. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancelda R, Pennesi G. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol. 2005;35(5): 1482–90.

25. Zhou K, Guo S, Tong S, Sun Q, Li F, Zhang X, Qiao Y, Liang G. Immunosuppression of human adipose-derived stem cells on T Cell subsets via the reduction of NF-kappaB activation mediated by PD-L1/PD-1 and Gal-9/TIM-3 pathways. Stem Cells Dev. 2018;27(17): 1191–202.

26. Li T, Zhang C, Zhao G, Zhang X, Hao M, Hassan S, Zhang M, Zheng H, Yang D, Liu L, Ghomi FM, et al. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma. Cancer Lett. 2020;477:19–30.

27. Liu Y, Song C, Shen F, Zhang J, Song SW. IGFBP2 promotes immunosuppression associated with its mesenchymal induc- tion and FcγRIIB phosphorylation in glioblastoma. PLoS ONE. 2019;14(9): e0222999.

28. Liso A, Capitanio N, Gerli R, Conese M. From fever to immunity: a new role for IGFBP-6? J Cell Mol Med. 2018;22(10): 4588–96.

29. Johann P-D, Vaegler M, Gieseke F, Mang P, Armeanu-Ebinger S, Kluba T, Handgretinger R, Müller I. Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity. BMC Cancer. 2010;10: 501.

30. Galland S, Vuille J, Martin P, Letovance I, Caignard A, Fregni G, Stamenkovic I. Tumor-derived mesenchymal stem cells use distinct mechanisms to block the activity of natural killer cell subsets. Cell Rep. 2017;20(12): 2891–905.

31. Ridge SM, Sullivan FJ, Glynn SA. Mesenchymal stem cells: key players in cancer progression. Mol Cancer. 2017;16(1): 31.